Browsing category:

FDA Approved 2010


Patients suffering from the rare neuromuscular disorder Lambert-Eaton myasthenic syndrome have recently received life changing news. On August 27, 2013 the FDA decided to grant Amifampridine Phosphate a Breakthrough Therapy Designation, also known as BTD.  Marketed by BioMarin as the brand name Firdapse, Amifampridine Phosphate offers a crucial new hope for patients enduring this fatal[…]

Read More

Cabazitaxel was approved by the FDA in 2010 as the brand name Jetvana, for the treatment of advanced prostate cancer. Cabazitaxel, CAS number 183133-96-2, is an anti-cancer medication that is typically prescribed alongside the steroid prednisone. Patients that have become resistant to docetaxel or other cancer treatments may find success with cabazitaxel. Adverse effects are[…]

Read More

Lurasidone CAS# 367514-87-2, is an atypical antipsychotic medication. Also known as the brand name Latuda, lurasidone is an effectual treatment for the symptoms of schizophrenia. As a second generation antipsychotic, or SGA, lurasidone is available in 20, 40, 80 and 120 milligram tablets. Latuda was approved by the FDA in October of 2010 for the[…]

Read More

Amifampridine, CAS# 54-96-6, is the first and only approved drug thus far for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome in adults. As a rare autoimmune disease, Lambert-Eaton Myasthenic Syndrome, also called LEMS, is typically caused by autoantibodies to voltage gated calcium channels, leading to a reduction in the amount of acetylcholine released from nerve[…]

Read More

As a kinase inhibitor, Lapatinib Ditosylate, CAS number 388082-78-8 is efficacious when used to treat metastatic breast cancer. The ability of lapatinib ditosylate to inhibit deviating active kinases within cancer cells, and prevent cell division, makes it an effective choice for patients with advanced breast cancer. Also known as Tykerb, which is marketed by GlaxoSmithKline,[…]

Read More